http://www.eidostx.com
Eidos Therapeutics, Inc. Company Intro
Targeting TTR amyloidosis at its source. Transthyretin (TTR) amyloidosis is a family of rare, devastating diseases with serious unmet medical needs.
Industry
Healthcare
Eidos Therapeutics, Inc. Headquaters
101 Montgomery Street
San Francisco,94104
United States
Eidos Therapeutics, Inc. Share price
14 Sep 2022 09:07 GMT
$0
0.0 (0 %)
Eidos Therapeutics, Inc. Market cap
$
WMC RANKING
2023
Eidos Therapeutics, Inc. # 128
BiotechnologyLatest Eidos Therapeutics, Inc. News
24 Mar 2023
BridgeBio Pharma Inc Shares Resume Trading After Positive ...
In May 2021, BridgeBio announced that one of its subsidiaries, Eidos Therapeutics, had received FDA approval for its drug, Tegsedi, to treat hereditary...
24 Mar 2023
BridgeBio Pharma Inc Shares Resume Trading After Positive ...
In May 2021, BridgeBio announced that one of its subsidiaries, Eidos Therapeutics, had received FDA approval for its drug, Tegsedi, to treat hereditary...
24 Mar 2023
BridgeBio Pharma Inc Shares Resume Trading After Positive ...
In May 2021, BridgeBio announced that one of its subsidiaries, Eidos Therapeutics, had received FDA approval for its drug, Tegsedi, to treat hereditary...
WMC Market Score
WMC Market to Revenue Score
Eidos Therapeutics, Inc. Market Financials
Revenue, Expenses, Profit
| Company | Currency | Revenue | Expense | Profit | Market Cap | WMC Sector Score |
| Eidos Therapeutics, Inc. | USD | $26,691 | $64,642 | $-37,835 | $ | 128 |
| Regeneron Pharmaceuticals, Inc. | USD | $9,197,600 | $3,997,800 | $4,003,800 | $754,300B | 1 |
| Vertex Pharmaceuticals Incorporated | USD | $6,414,881 | $2,617,257 | $2,762,032 | $713,610B | 2 |
| Alexion Pharmaceuticals, Inc. | USD | $6,261,601 | $2,747,200 | $681,800 | $ | 3 |
| Incyte Corporation | USD | $2,702,913 | $2,048,306 | $478,480 | $150,520B | 4 |
Market Analytics
Company Search vs Top 4 Industry Competitors
Total Eidos Therapeutics, Inc. Social Followers vs Top 4 Industry Competitors
Eidos Therapeutics, Inc. Post vs Top 4 Industry Competitors
Eidos Therapeutics, Inc. Digital Footprint By Size vs Top 4 Industry Competitors
Eidos Therapeutics, Inc. Digital Footprint By Change Rate vs Top 4 Industry Competitors
Eidos Therapeutics, Inc. WMC Market Score Calculations
| Details | Revenue | Total Social Followers | Total Social Posts | Search Volume | Digital Footprint Size | Digital change (New Pages) | WMC Market Score |
| Eidos Therapeutics, Inc. | 0.29 | 0 | 0 | 0 | 0 | 0 | 0 |
| Regeneron Pharmaceuticals, Inc. | 100 | 25.50 | 16.15 | 22 | 0 | 0 | 28.52 |
| Vertex Pharmaceuticals Incorporated | 69.75 | 35.68 | 8.95 | 33 | 0 | 0 | 34.78 |
| Alexion Pharmaceuticals, Inc. | 68.08 | 100 | 100 | 22 | 0 | 0 | 100 |
| Incyte Corporation | 29.39 | 5.03 | 0.04 | 100 | 0 | 0 | 47.37 |
Book a demo
Book a free one-on-one demo with one of our team and see exactly how the WMC business intelligence platform can help you protect and grow revenue.
* required fields
You'll learn how to:
- 1. Automatically monitor your entire digital landscape including competitors
- 2. View all new industry activity in real time
- 3. Monitor your position in your industry
- 4. Enrich your reports and strategy
- 5. Empower your teams with knowledge
